89 related articles for article (PubMed ID: 38265633)
1. Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England.
Brown J; Harrow B; Marciniak A; McCarthy C; Houchard A; Cirneanu L; Protheroe A
Drugs Real World Outcomes; 2024 Jan; ():. PubMed ID: 38265633
[TBL] [Abstract][Full Text] [Related]
2. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.
Barthélémy P; Dutailly P; Qvick B; Perrot V; Verzoni E
Future Oncol; 2024 Apr; 20(13):811-819. PubMed ID: 37403652
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.
Tomida R; Takahashi M; Matsushita Y; Kojima T; Yamana K; Kandori S; Bando Y; Nishiyama N; Yamashita S; Taniguchi H; Monji K; Ishiyama R; Tatarano S; Masui K; Matsuda A; Kaneko T; Motoshima T; Shiraishi Y; Kira S; Murashima T; Hara H; Matsumura M; Kitamura H; Miyake H; Furukawa J;
Clin Genitourin Cancer; 2024 Apr; ():102094. PubMed ID: 38714434
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
Gebrael G; Jo Y; Mathew Thomas V; Li H; Sayegh N; Tripathi N; Srivastava A; Nordblad B; Dal E; Narang A; Brundage J; Campbell P; Galarza Fortuna G; Hage Chehade C; Maughan BL; Agarwal N; Swami U
Cancer; 2024 Apr; ():. PubMed ID: 38564301
[TBL] [Abstract][Full Text] [Related]
5. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
[No Abstract] [Full Text] [Related]
6. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
Gross-Goupil M; Bodnar L; Campbell MT; Michael A; Venugopal B; Żołnierek J; Dutailly P; Procopio G; Albiges L
Clin Genitourin Cancer; 2024 Feb; 22(1):84-97. PubMed ID: 38101983
[TBL] [Abstract][Full Text] [Related]
7. Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective-prospective cohort multicentre study.
Cesas A; Urbonas V; Tulyte S; Janciauskiene R; Liutkauskiene S; Grabauskyte I; Gaidamavicius I
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6979-6988. PubMed ID: 36847839
[TBL] [Abstract][Full Text] [Related]
8. New approaches to first-line treatment of advanced renal cell carcinoma.
George DJ; Lee CH; Heng D
Ther Adv Med Oncol; 2021; 13():17588359211034708. PubMed ID: 34527080
[TBL] [Abstract][Full Text] [Related]
9. RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain.
Badiola LB; Milagro NL; Lavín DC; Peraita SL; Ibarbia MA; Kareaga MM; Fernández Del Rivero TP; Otero DSP; López VA; Fernández CÁ; Emborujo AL; Arnaiz IG; Rodríguez RF; Sagastibeltza N; Duran I;
Semin Oncol; 2024 Mar; ():. PubMed ID: 38604897
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.
Kanzaki H; Ogasawara S; Okubo T; Itokawa N; Yoshino R; Fujimoto K; Kogure T; Yumita S; Ishino T; Ogawa K; Iwanaga T; Nakagawa M; Fujiwara K; Kojima R; Koroki K; Inoue M; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Itobayashi E; Atsukawa M; Kato J; Kato N
Drugs Real World Outcomes; 2023 Dec; 10(4):513-520. PubMed ID: 37466822
[TBL] [Abstract][Full Text] [Related]
11. PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors.
Stokes ME; Calvo V; Fujisawa S; Dudgeon C; Huang S; Ballal N; Shen L; Gasparek J; Betzenhauser M; Taylor SJ; Staschke KA; Rigby AC; Mulvihill MJ; Bose N; Lightcap ES; Surguladze D
Clin Cancer Res; 2023 Dec; 29(23):4870-4882. PubMed ID: 37733811
[TBL] [Abstract][Full Text] [Related]
12. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
Graham J; Ghosh S; Breau RH; Wood L; Tanguay S; Bosse D; Lalani AK; Bhindi B; Heng D; Finelli A; Fallah-Rad N; Castonguay V; Basappa NS; Soulières D; Pouliot F; Kollmannsberger C; Bjarnason GA
Clin Genitourin Cancer; 2024 Feb; ():102060. PubMed ID: 38521648
[TBL] [Abstract][Full Text] [Related]
13. Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.
Kudo M; Kang YK; Park JW; Qin S; Inaba Y; Assenat E; Umeyama Y; Lechuga MJ; Valota O; Fujii Y; Martini JF; Williams JA; Obi S
Liver Cancer; 2018 May; 7(2):148-164. PubMed ID: 29888205
[TBL] [Abstract][Full Text] [Related]
14. The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong-A Territory-Wide Cohort Study.
Wong JS; Dong Y; Tang V; Leung T; Yeung CSY; Tai A; Law A; Shum T; Kwok GG; Li BC; Leung R; Chiu J; Ma KW; She WH; Tsang J; Cheung TT; Yau T
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33919277
[TBL] [Abstract][Full Text] [Related]
15. Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Renal Cell Carcinoma in England: A Retrospective Cohort Study.
Das P; Booth A; Donaldson R; Berfeld N; Nordstrom B; Carroll R; Dhokia P; Clark A; Vaz L
Clin Genitourin Cancer; 2024 Mar; ():102081. PubMed ID: 38641444
[TBL] [Abstract][Full Text] [Related]
16. Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.
Narayan V; Haas NB
Int J Nephrol Renovasc Dis; 2016; 9():65-72. PubMed ID: 27099525
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma.
Iuliani M; Simonetti S; Pantano F; Ribelli G; Di Martino A; Denaro V; Vincenzi B; Russo A; Tonini G; Santini D
Biology (Basel); 2021 Aug; 10(8):. PubMed ID: 34440012
[TBL] [Abstract][Full Text] [Related]
18. Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma.
Sharma A; Elias R; Christie A; Williams NS; Pedrosa I; Bjarnason GA; Brugarolas J
Kidney Cancer; 2022; 6(1):69-79. PubMed ID: 36743424
[TBL] [Abstract][Full Text] [Related]
19. Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis.
Van Nguyen T; Hamdan D; Falgarone G; Do KH; Van Le Q; Pamoukdjian F; Bousquet G
Target Oncol; 2024 May; ():. PubMed ID: 38761350
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.
Scirocchi F; Napoletano C; Pace A; Rahimi Koshkaki H; Di Filippo A; Zizzari IG; Nuti M; Rughetti A
Front Oncol; 2021; 11():755433. PubMed ID: 34745989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
